Kyowa Kirin Email Format

Pharmaceutical Manufacturing
501-1,000 employees
Princeton, NJ, USA

Kyowa Kirin is a global specialty pharmaceutical company that applies advanced biotechnologies to discover and deliver novel medicines for difficult-to-treat diseases.

Find contacts at Kyowa Kirin

Search our verified sources for decision-makers, emails, and titles.

Start searching
VERIFIED BY CLAY

first.last@kyowakirin.com

Company Overview

Industry
Pharmaceutical Manufacturing
Founded
1949
Headquarters
Princeton, NJ, USA
Revenue
$250M-$500M
FUNDING Stage
Public
Key Executives
Abdul Mullick (Representative Director, President and Chief Executive Officer (CEO)), Koji Igarashi (Chief Financial Officer (CFO)), Mitsuru Kameyama (Chief Digital Transformation Officer (CDXO))

Tech Stack

Treasure Data

Analytics

Signup

to know

Signup

to know

Signup

to know

Key Executives

Chief Executive Officer

Find the current person →

Chief Finance Officer

Find the current person →

Chief Operating Officer

Find the current person →

Chief Technology Officer

Find the current person →

Chief Marketing Officer

Find the current person →

Chairman

Find the current person →

4.9/5 on G2
40K+ GTM professionals
SOC 2 Type II certified

Frequently Asked Questions

What is the email format of Kyowa Kirin?

Kyowa Kirin uses the first.last format, so Jane Smith would be jane.smith@kyowakirin.com.

What are Kyowa Kirin's three main disease focus areas?

Kyowa Kirin concentrates its research and commercial efforts on three priority areas: Bone and Mineral disorders, Intractable Hematological Diseases and Hemato-Oncology, and Rare Diseases, including conditions like X-linked hypophosphatemia and cutaneous T-cell lymphoma.

Where does Kyowa Kirin have research and manufacturing facilities in North America?

Kyowa Kirin operates a research and discovery center in La Jolla, California, and is building its first North American biologic manufacturing site in Sanford, North Carolina, which is expected to be fully operational by 2027.

What is Kyowa Kirin's rocatinlimab program targeting in 2026?

Rocatinlimab is Kyowa Kirin's anti-OX40 monoclonal antibody in development for moderate-to-severe atopic dermatitis. Kyowa Kirin regained full control of the program in January 2026 and plans to submit for regulatory approval in the U.S. in the first half of 2026.

How can I find and verify a Kyowa Kirin contact's email address for outreach?

Since Kyowa Kirin follows the first.last@kyowakirin.com format, you can build most addresses directly from a contact's name. A tool like Clay can help you verify those addresses and enrich your prospect records with additional details before reaching out.

Share Article

Get access to more people and company data using Clay

Leverage the power of 100+ data providers for industry-leading data coverage & quality.

4.9 rating

More Articles